GLYCOMICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On March 11, 2024, Bruker Corporation announced progress in immunopeptidomics, glycoproteomics, and other Collision Cross Section (CCS) -enabled 4D proteomics workflows. Bruker Corporation's rapid developments in deep, at-scale proteomics, glycomics, and peptidomics research solutions complement its other performance-leading life-science technologies for the post-genomic era. Together, they enable post-genomic molecular and cell biology research, providing critical insights into disease biology and biomarkers for next-generation molecular diagnostics and medication development.
• On January 30, 2024, Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, and Navinci Diagnostics, the leader in breakthrough in situ proximity ligation assay-based solutions, announced the signing of an agreement. This collaboration aims to create cutting-edge biomarker discovery techniques that will identify particular protein glycosylation in tissue samples for the first time.
• In April 2021, BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, and the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centers of Excellence, announced a collaboration to translate glycomics research into potential treatments for patients with genetic diseases. BridgeBio Pharma, Inc. will collaborate with GlycoNet researchers to identify research projects that have the potential to become treatments for genetic illnesses.